What happened
Celltrion Pharm filed provisional (unaudited) separate results for FY2025: revenue of US$367M, operating profit of US$38.4M and net income of US$26.5M.
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$367M |
|---|---|
| Operating profit | US$38.4M |
| Net income | US$26.5M |
| Period | FY2025 (separate) |
| Filed | 2026-02-05, Operating results (preliminary) (fair disclosure) |
| Source | DART rcept 20260205900152 → open original filing |
Source: DART. Information only, not investment advice.